SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ALTHX (MC $9 M) Alzheimer & Parkinson readout imminent

28 Nov 2019 03:03 AM <--
27 Nov 2019 05:33 AM

Return to ALTHX (MC $9 M) Alzheimer & Parkinson readout imminent
 
Theranexus (ALTHX) Market Cap laughable $9 M /Cash $12.3 M / Shares Out 3.6 M/ Alzheimer P1b Data this Quarter /Parkinson P2 data in early Q1 2020 = The CHEAPEST Alzheimer/ Parkinson stock on planet ...This could be more than just a potential 10 bagger

Alzheimer's disease-related neurocognitive disorders --The Phase 1b results are expected in Q4 2019.
excessive daytime sleepiness in Parkinson disease -- The Phase 2 results are expected in Q1 2020

Theranexus (Euronext: ALTHX) <<< French company

Market Cap: €8.73 M (~ US$ 9.62 M)
Cash €11.2 Million ( US$ 12.3 M )

Shares Out 3.6 Million

Homepage
theranexus.com

theranexus.com

Drug Candidate THN102 –Parkinson's Disease and NarcolepsyOn 24 September, Theranexus announced the recruitment of its last patient with Parkinson's disease naive of any treatment for this pathology to its Phase II clinical trial which aims to evaluate the tolerance and efficacy of its drug candidate THN102 (modafinil/flecainide combination) on non-motor symptoms of the disease (drowsiness, attention and cognitive disorders).This triad, a major unmet medical need in the disease, has a very high market value potential (estimated at over $2 billion). The results for THN102 are expected in Q1 2020.

Drug Candidate THN201 –Completion of recruitment for the Phase Ib trial to treat Alzheimer's disease-related neurocognitive disorders On 17 September, Theranexus announced inclusion of the last healthy subject in its Phase Ib trial comparing the pharmacological efficacy of its drug candidate THN201 with the standard-of-care treatment in Alzheimer's disease-related neurocognitive disorders.The results are expected in Q4 2019.